haemaLogiX, a Sydney, Australia-based biotech company, raised $10M in funding.
The round was led by Platinum Asset Management via its Platinum International Health Care Fund.
The company intends to use the funds to support manufacturing of the next batch of the Kappa antibody plus the conduct of a higher dose, 30mg/kg, monotherapy study and prepare for two further studies.
Led by Bryce Carmine, Chairman and CEO, HaemaLogiX provides immuno-oncology and immune therapies for patients with blood cancers. The company is focused on the development and commercialization of monoclonal antibodies (KappaMab) for the potential treatment of multiple myeloma (and potentially other blood cancers).
Final results from the Phase IIb clinical trial are expected to be published in late 2021.
The company also plans to progress its antibody for lambda-type multiple myeloma (which account for 30% of multiple myeloma patients) and continue activities to secure pharmaceutical partners for technology development, which may generate income through a licence or asset sale.
FinSMEs
09/09/2021